Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million

Merck today announced the expansion of its strategic, corporate venture capital arm M Ventures.

Merck, a leading science and technology company, today announced the expansion of its strategic, corporate venture capital arm M Ventures. The new investment of € 600 million allocated to M Ventures will be deployed over the next five years. This is the third increase in financial commitment announced by Merck since the creation of M Ventures in 2009. The increase will be used to further grow both the number and size of investments.

“Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems,” said Belén Garijo, Chair of the Executive Board and CEO of Merck.

“Given its extensive expertise in identifying new technologies and capabilities, we aim to increase our annual financial investments. This will enable M Ventures to continue to advance our pioneering innovation strategy, to deliver sustainable business performance and to be a catalyst for innovative companies to develop breakthrough technologies”, she added.

Since inception, M Ventures has been instrumental in the development of over 80 global companies from creation to exit, helping advance multiple medicines and technologies to market launch. M Ventures will continue to invest in visionary companies that find new ways to treat the most challenging diseases, empower scientists with cutting-edge research and development tools, develop new technologies to improve the way in which information is accessed, stored, processed, and displayed and provide novel solutions for increased sustainability in the science and technology ecosystem.

The new capital will allow M Ventures to continue to utilise its expertise to create and finance a new and larger portfolio of innovative companies that align with the future strategies of Merck businesses.

In the last two years, M Ventures has validated its dual foci as a strategic and financial corporate venture capital fund with several of its companies establishing collaborations with Merck, and others creating strong financial returns through acquisitions or public market listings supporting its evergreen remit.

Gangolf Schrimpf photo Merck KGaA